Report structure
1. Case identification
Case reference, date of issue, specialty, reviewing clinician, registration jurisdiction and the clinical question you asked.
2. Records reviewed
An itemised list of every document reviewed, with document type and date, so it is clear what the opinion is and is not based on.
3. Clinical chronology
A dated timeline of presentation, investigations, histology, interventions and treatment response, reconciled across all sources.
4. Imaging and pathology review
Comment on reported findings, staging descriptors, receptor or biomarker status, and any discrepancy between reports or between imaging and histology.
5. Assessment of completeness
Whether the documented workup is consistent with current guidance, and which investigations commonly indicated for this presentation are not evidenced in the records.
6. Management options
Recognised options with the evidence base, typical toxicity profile and the trade-offs a patient would reasonably want explained.
7. Agreement and difference
Where the reviewer supports the documented plan, where they would raise an alternative, and where genuine clinical uncertainty exists.
8. Questions for your doctor
A prioritised, plainly worded list you can take to your next appointment.
9. Safety netting
Symptoms that should prompt same-day contact with your clinical team or emergency services.
10. Signature
Reviewer name, specialty, registration details, date and digital signature. Multidisciplinary reports carry a signature from every participating specialist.
Anonymised excerpts
These illustrative extracts are composites written for demonstration. They do not relate to a real identifiable patient and are not medical advice.
Oncology · Breast
Is the proposed adjuvant regimen consistent with current guidance?
The histopathology report describes an invasive ductal carcinoma of no special type, grade 2, oestrogen receptor positive, HER2 negative, with one of four sentinel nodes involved. The documented plan of adjuvant chemotherapy followed by endocrine therapy is consistent with current guidance for this profile. The records do not evidence a genomic recurrence-score assay; where available, this is commonly used in node-limited, ER-positive, HER2-negative disease to inform whether chemotherapy adds benefit. This is a reasonable point to raise with the treating oncologist.
Cardiology · Heart failure
Has guideline-directed medical therapy been optimised?
The echocardiogram documents a left ventricular ejection fraction of 32% with moderate functional mitral regurgitation. The medication list evidences a beta blocker and an ACE inhibitor. The records do not evidence a mineralocorticoid receptor antagonist or an SGLT2 inhibitor, both of which form part of contemporary four-pillar therapy for heart failure with reduced ejection fraction. Suitability depends on renal function, potassium and blood pressure, which the treating cardiologist is best placed to assess.
Neurology · Demyelination
Do the findings support the working diagnosis?
MRI reports describe periventricular and juxtacortical T2 hyperintense lesions with one enhancing lesion. Cerebrospinal fluid analysis documents unmatched oligoclonal bands. Taken together the documented findings are consistent with dissemination in space and time as described in current diagnostic criteria. Alternative causes of white matter change documented as excluded include B12 deficiency and vasculitis screening; no serological testing for aquaporin-4 or MOG antibodies is evidenced in the records supplied.
MedReview 365 provides independent, informational second opinions based on the records you supply. We do not diagnose, prescribe, or replace the care of your treating clinician. Discuss any recommendation with your own medical team, and call your local emergency number for urgent or deteriorating symptoms.